Phenytoin teratogenicity: Hypoxia marker and effects on embryonic heart rhythm suggest an hERG-related mechanism

Birth Defects Research Part A - Clinical and Molecular Teratology

Volumn 73, Issue 3, 2005, Pages 146-153

  Danielsson, Bengt R ^a   Johansson, Alf ^b   Danielsson, Christian ^a   Azarbayjani, Faranak ^a   Blomgren, Bo ^a,b   Sköld, Anna Carin ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Delayed rectifier potassium channel; Embryonic arrhythmia; HERG; Hypoxia reoxygenation damage; IKr; Mouse; Phenytoin; Teratogenicity

Indexed keywords

PHENYTOIN; PIMONIDAZOLE; POTASSIUM CHANNEL HERG; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRADYCARDIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; EMBRYO; EMBRYO CULTURE; FETUS; HEART ARRHYTHMIA; HEART RHYTHM; HYPOXIA; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; REOXYGENATION; TERATOGENICITY;

ANIMALS; ANOXIA; ANTICONVULSANTS; CATION TRANSPORT PROTEINS; ETHER-A-GO-GO POTASSIUM CHANNELS; FEMALE; HEART; MICE; MICE, INBRED C57BL; PHENYTOIN; POTASSIUM CHANNELS, VOLTAGE-GATED; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS;

ANIMALIA;

EID: 16444375436     PISSN: 15420752     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdra.20124     Document Type: Article

References (48)

1. Abrahamsson C, Palmer M, Ljung B, et al. 1994. Induction of rhythm abnormalities in the fetal rat heart. A tentative mechanism for the embryotoxic effect of the class III antiarrhythmic agent almokalant. Cardiovasc Res 28:337-344.
2. Azarbayjani F, Danielsson BR. 2001. Phenytoin-induced cleft palate: evidence for embryonic cardiac bradyarrhythmia due to inhibition of delayed rectifier K+ channels resulting in hypoxia-reoxygenation damage. Teratology 63:152-160.
3. Azarbayjani F, Danielsson BR. 2002. Embryonic arrhythmia by inhibition of HERG channels: a common hypoxia-related teratogenic mechanism for antiepileptic drugs? Epilepsia 43:457-468.
4. Brent RL, Franklin JB. 1960. Uterine vascular clamping: new procedure for the study of congenital malformations. Science 132:89-91.
5. d'Argy R, Sperber GO, Larsson BS, Ullberg S. 1990. Computer-assisted quantification and image processing of whole-body autoradiograms. J Pharmacol Methods 24:165-181.
6. Danielson MK, Danielsson BR, Marchner H, et al. 1992. Histopathological and hemodynamic studies supporting hypoxia and vascular disruption as explanation to phenytoin teratogenicity. Teratology 46:485-497.
7. Danielsson BR, Danielson M, Rundqvist E, Reiland S. 1992. Identical phalangeal defects induced by phenytoin and nifedipine suggest fetal hypoxia and vascular disruption behind phenytoin teratogenicity. Teratology 45:247-258.
8. Danielsson BR, Danielson K, Tomson T. 1995. Phenytoin causes phalangeal hypoplasia in the rabbit fetus at clinically relevant free plasma concentrations. Teratology 52:252-259.
9. Danielsson BR, Azarbayjani F, Sköld AC, Webster WS. 1997. Initiation of phenytoin teratogenesis: pharmacologically induced embryonic bradycardia and arrhythmia resulting in hypoxia and possible free radical damage at reoxygenation. Teratology 56:271-281.
10. Danielsson B, Sköld AC, Azarbayjani F, et al. 2000. Pharmacokinetic data support pharmacologically induced embryonic dysrhythmia as explanation to fetal hydantoin syndrome in rats. Toxicol Appl Pharmacol 163:164-175.
11. Danielsson BR, Sköld AC, Azarbayjani F. 2001. Class III antiarrhythmics and phenytoin: teratogenicity due to embryonic cardiac dysrhythmia and reoxygenation damage [Review]. Curr Pharm Des 7:787-802.
12. Danielsson BR, Lansdell K, Patmore L, Tomson T. 2003a. Phenytoin and phenobarbital inhibit human HERG potassium channels. Epilepsy Res 55:147-157.
13. Danielsson BR, Sköld AC, Johansson A, et al. 2003b. Teratogenicity by the hERG potassium channel blocking drug almokalant: use of hypoxia marker gives evidence for a hypoxia-related mechanism mediated via embryonic arrhythmia. Toxicol Appl Pharmacol 193:168-176.
14. Danielsson BR, Webster WS. 1997. Cardiovascular active drugs. In: Kavlock RJ, Daston GP, editors. Drug toxicity in embryonic development II; Advances in understanding mechanisms of birth defects: mechanistic understanding of human developmental toxicants. Berlin: Springer Heidelberg, pp. 161-190.
15. Dansky LV, Finnell RH. 1991. Parental epilepsy, anticonvulsant drugs, and reproductive outcome: epidemiologic and experimental findings spanning three decades; 2: Human studies. Reprod Toxicol 5:301-335.
16. Davies MP, An RH, Doevendans P, et al. 1996. Developmental changes in ionic channel activity in the embryonic murine heart. Circ Res 78:15-25.
17. Desesso JM. 1997. Comparative embryology. In: Hood RD, editor. Handbook of developmental toxicology. Boca Raton: CRC Press, pp. 111-174.
18. Fantel AG, Person RE, Tumbic RW, et al. 1995. Studies of mitochondria in oxidative embryotoxicity. Teratology 52:190-195.
19. Fantel AG. 1996. Reactive oxygen species in developmental toxicity: review and hypothesis. Teratology 53:196-217.
20. Finnell RH, Dansky LV. 1991. Parental epilepsy, anticonvulsant drugs, and reproductive outcome: epidemiologic and experimental findings spanning three decades; 1: Animal studies. Reprod Toxicol 5:281-299.
21. Franklin JB, Brent RL. 1964. The effect of uterine vascular clamping on the development of rat embryos three to fourteen days old. J Morphol 115:273-290.
22. Grabowski CT. 1970. Embryonic oxygen deficiency - a physiological approach to analysis of teratological mechanisms. In: Woollam DHM, editor. Advances in teratology. London: Logos Press Ltd. pp. 125-169.
23. Hanson JW. 1986. Teratogen update: fetal hydantoin effects. Teratology 33:349-353.
24. Harris C. 1997. Hypoxia and altered redox status in embryotoxicity. In: Kavlock RJ, Daston GP, editors. Drug toxicity in embryonic development I; Advances in understanding mechanisms of birth defects: mechanistic understanding of human developmental toxicants. Berlin: Springer Heidelberg, pp. 517-546.
25. Holmes LB, Harvey EA, Coull BA, et al. 2001. The teratogenicity of anticonvulsant drugs. N Engl J Med 344:1132-1138.
26. Kelly TE, Edwards P, Rein M, et al. 1984. Teratogenicity of anticonvulsant drugs. II: A prospective study. Am J Med Genet 19:435-443.
27. Langheinrich U, Vacun G, Wagner T. 2003. Zebrafish embryos express an orthologue of HERG and are sensitive toward a range of QT-prolonging drugs inducing severe arrhythmia. Toxicol Appl Pharmacol 193: 370-382.
28. Lee YM, Jeong CH, Koo SY, et al. 2001. Determination of hypoxic region by hypoxia marker in developing mouse embryos in vivo: a possible signal for vessel development. Dev Dyn 220:175-186.
29. Leist KH, Grauwiler J. 1974. Fetal pathology in rats following uterine-vessel clamping on day 14 of gestation. Teratology 10:55-67.
30. Lu MC, Sammel MD, Cleveland RH, et al. 2000. Digit effects produced by prenatal exposure to antiepileptic drugs. Teratology 61:277-283.
31. Lyon HM, Holmes LB, Huang T. 2003. Multiple congenital anomalies associated with in utero exposure of phenytoin: possible hypoxic ischemic mechanism? Birth Defects Res Part A Clin Mol Teratol 67:993-996.
32. Marks TA, Terry RD. 1996. Developmental toxicity of ibutilide fumarate in rats after oral administration. Teratology 54:157-164.
33. McClain RM, Langhoff L. 1980. Teratogenicity of diphenylhydantoin in the New Zealand white rabbit. Teratology 21:371-379.
34. McGuirk CK, Westgate MN, Holmes LB. 2001. Limb deficiencies in newborn infants. Pediatrics 108:E64.
35. New DA. 1978. Whole-embryo culture and the study of mammalian embryos during organogenesis. Biol Rev Camb Philos Soc 53:81-122.
36. Newberger DS, Blyth SA. 2003. Hypothermia and phenytoin toxicity. Clin Neuropharmacol 26:172-173
37. Nobile M, Vercellino P. 1997. Inhibition of delayed rectifier K+ channels by phenytoin in rat neuroblastoma cells. Br J Pharmacol 120:647-652.
38. Orup HI Jr, Holmes LB, Keith DA, Coull BA. 2003. Craniofacial skeletal deviations following in utero exposure to the anticonvulsant phenytoin: monotherapy and polytherapy. Orthod Craniofac Res 6:2-19.
39. Pennell PB. 2003. The importance of monotherapy in pregnancy. Neurology 60:S31-S38.
40. Sköld AC, Danielsson C, Linder B, Danielsson BR. 2002. Teratogenicity of the IKr-blocker cisapride: relation to embryonic cardiac arrhythmia. Reprod Toxicol 16:333-342.
41. Spence SG, Vetter C, Hoe CM. 1994. Effects of the class III antiarrhythmic, dofetilide (UK-68,798) on the heart rate of midgestation rat embryos, in vitro. Teratology 49:282-292.
42. Tomson T, Kennebäck G. 1997. Arrhythmia, heart rate variability, and antiepileptic drugs. Epilepsia 38:S48-S51.
43. Varia MA, Calkins-Adams DP, Rinker LH, et al. 1998. Pimonidazole: a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma. Gynecol Oncol 71:270-277.
44. Wang L, Feng ZP, Kondo CS, et al. 1996. Developmental changes in the delayed rectifier K+ channels in mouse heart. Circ Res 79:79-85.
45. Webster WS, Brown-Woodman PD. 1990. Cocaine as a cause of congenital malformations of vascular origin: experimental evidence in the rat. Teratology 41:689-697.
46. Webster WS, Brown-Woodman PD, Snow MD, Danielsson BR. 1996. Teratogenic potential of almokalant, dofetilide, and d-sotalol: drugs with potassium channel blocking activity. Teratology 53:168-175.
47. Winn LM, Wells PG. 1999. Maternal administration of superoxide and catalase in phenytoin teratogenicity. Free Radic Biol Med 26:266-274.
48. Witchel HJ, Hancox JC. 2000. Familial and acquired long QT syndrome and the cardiac rapid delayed rectifier potassium current. Clin Exp Pharmacol Physiol 27:753-766.